Apogee Therapeutics

Visit Website

Clinical-stage biotech developing best-in-class antibody therapies for inflammatory and immunological diseases, led by its extended half-life anti-IL-13 antibody zumilokibart (APG777) for atopic dermatitis and asthma.

Headquarters

Waltham, USA

Year Founded

2022

Founders

Michael Henderson (CEO), Paragon Therapeutics spinout

Country

United States

Financial Information

Funding Stage

Public (Nasdaq: APGE)

Recent Funding

$149M

Funding By

Fairmount, Venrock, Cormorant, plus public markets

Core Technology

Extended half-life antibody engineering (anti-IL-13)

Product Type

Drug

Pipeline Stage (Very Important)

Phase II (Phase 3-ready)

Regulatory Status

IND Filed: Yes
FDA/EMA Status: FDA Clinical
Clinical Trial Registration: APEX Phase 2 (atopic dermatitis)
Patents / IP Status: Filed

Partnerships

Pharma Collaborations

Paragon Therapeutics

Academic / Hospital Tie-ups

None disclosed

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

Best-in-class half-life extended anti-IL-13 with every 3-6 month dosing potential